408 related articles for article (PubMed ID: 1353504)
1. The effect of changing somatostatin tone on the pituitary growth hormone and thyroid-stimulating hormone responses to their respective releasing factor stimuli.
Spoudeas HA; Matthews DR; Brook CG; Hindmarsh PC
J Clin Endocrinol Metab; 1992 Aug; 75(2):453-8. PubMed ID: 1353504
[TBL] [Abstract][Full Text] [Related]
2. Impaired inhibitory effects of somatostatin on growth hormone (GH)-releasing hormone stimulation of GH secretion after short term infusion.
Kelijman M; Frohman LA
J Clin Endocrinol Metab; 1990 Jul; 71(1):157-63. PubMed ID: 1973420
[TBL] [Abstract][Full Text] [Related]
3. The role of the cholinergic pathway in growth hormone feedback.
Kelijman M; Frohman LA
J Clin Endocrinol Metab; 1991 May; 72(5):1081-7. PubMed ID: 1902484
[TBL] [Abstract][Full Text] [Related]
4. Arginine stimulates growth hormone secretion by suppressing endogenous somatostatin secretion.
Alba-Roth J; Müller OA; Schopohl J; von Werder K
J Clin Endocrinol Metab; 1988 Dec; 67(6):1186-9. PubMed ID: 2903866
[TBL] [Abstract][Full Text] [Related]
5. Pyridostigmine-mediated growth hormone release: evidence for somatostatin involvement.
Wehrenberg WB; Wiviott SD; Voltz DM; Giustina A
Endocrinology; 1992 Mar; 130(3):1445-50. PubMed ID: 1347008
[TBL] [Abstract][Full Text] [Related]
6. Effect of enhancement of endogenous cholinergic tone with pyridostigmine on the dose-response relationships of growth hormone (GH)-releasing hormone-induced GH secretion in normal subjects.
Peñalva A; Muruais C; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1990 Feb; 70(2):324-7. PubMed ID: 2105328
[TBL] [Abstract][Full Text] [Related]
7. Cholinergic receptor activation by pyridostigmine restores growth hormone (GH) responsiveness to GH-releasing hormone administration in obese subjects: evidence for hypothalamic somatostatinergic participation in the blunted GH release of obesity.
Cordido F; Casanueva FF; Dieguez C
J Clin Endocrinol Metab; 1989 Feb; 68(2):290-3. PubMed ID: 2493023
[TBL] [Abstract][Full Text] [Related]
8. The decrease in growth hormone (GH) response after repeated stimulation with GH-releasing hormone is partly caused by an elevation of somatostatin tonus.
Reichardt B; Schrader M; Mojto J; Mehltretter G; Müller OA; Schopohl J
J Clin Endocrinol Metab; 1996 May; 81(5):1994-8. PubMed ID: 8626871
[TBL] [Abstract][Full Text] [Related]
9. Role of the serotonin receptor subtype 5-HT1D on basal and stimulated growth hormone secretion.
Mota A; Bento A; Peñalva A; Pombo M; Dieguez C
J Clin Endocrinol Metab; 1995 Jun; 80(6):1973-7. PubMed ID: 7775648
[TBL] [Abstract][Full Text] [Related]
10. Activation of cholinergic neurotransmission by pyridostigmine reverses the inhibitory effect of hyperglycemia on growth hormone (GH) releasing hormone-induced GH secretion in man: does acute hyperglycemia act through hypothalamic release of somatostatin?
Peñalva A; Burguera B; Casabiell X; Tresguerres JA; Dieguez C; Casanueva FF
Neuroendocrinology; 1989 May; 49(5):551-4. PubMed ID: 2566942
[TBL] [Abstract][Full Text] [Related]
11. Effect of central cholinergic neurotransmission enhancement by pyridostigmine on the growth hormone secretion elicited by clonidine, arginine, or hypoglycemia in normal and obese subjects.
Cordido F; Dieguez C; Casanueva FF
J Clin Endocrinol Metab; 1990 May; 70(5):1361-70. PubMed ID: 2159483
[TBL] [Abstract][Full Text] [Related]
12. Effect of pyridostigmine on the thyroid-stimulating hormone response to thyrotropin-releasing hormone in abstinent alcoholics.
Coiro V; Vescovi PP
Alcohol Clin Exp Res; 1997 Oct; 21(7):1308-11. PubMed ID: 9347094
[TBL] [Abstract][Full Text] [Related]
13. Studies of growth hormone secretion in calorically restricted dogs: effect of cholinergic agonists and antagonists, glucose and thyrotropin-releasing hormone.
Arce VM; Cella SG; Locatelli V; Müller EE
Neuroendocrinology; 1991 May; 53(5):467-72. PubMed ID: 1908062
[TBL] [Abstract][Full Text] [Related]
14. Cholinergic control of growth hormone (GH) responses to GH-releasing hormone in insulin dependent diabetics: evidence for attenuated hypothalamic somatostatinergic tone and decreased GH autofeedback.
Ismail IS; Scanlon MF; Peters JR
Clin Endocrinol (Oxf); 1993 Feb; 38(2):149-57. PubMed ID: 8094648
[TBL] [Abstract][Full Text] [Related]
15. Effects of a prolonged growth hormone (GH)-releasing peptide infusion on pulsatile GH secretion in normal men.
Jaffe CA; Ho PJ; Demott-Friberg R; Bowers CY; Barkan AL
J Clin Endocrinol Metab; 1993 Dec; 77(6):1641-7. PubMed ID: 7903313
[TBL] [Abstract][Full Text] [Related]
16. Interaction of the growth hormone releasing peptide hexarelin with somatostatin.
Massoud AF; Hindmarsh PC; Brook CG
Clin Endocrinol (Oxf); 1997 Nov; 47(5):537-47. PubMed ID: 9425393
[TBL] [Abstract][Full Text] [Related]
17. Melatonin stimulates growth hormone secretion through pathways other than the growth hormone-releasing hormone.
Valcavi R; Zini M; Maestroni GJ; Conti A; Portioli I
Clin Endocrinol (Oxf); 1993 Aug; 39(2):193-9. PubMed ID: 8370132
[TBL] [Abstract][Full Text] [Related]
18. Growth hormone responses to growth hormone-releasing hormone and hexarelin in fed and fasted dogs: effect of somatostatin infusion or pretreatment with pirenzepine.
Rigamonti AE; Marazzi N; Cella SG; Cattaneo L; Müller EE
J Endocrinol; 1998 Feb; 156(2):341-8. PubMed ID: 9518881
[TBL] [Abstract][Full Text] [Related]
19. Pyridostigmine blocks the inhibitory effect of glucocorticoids on growth hormone-releasing hormone stimulated growth hormone secretion in normal man.
Giustina A; Girelli A; Doga M; Bodini C; Bossoni S; Romanelli G; Wehrenberg WB
J Clin Endocrinol Metab; 1990 Sep; 71(3):580-4. PubMed ID: 2118535
[TBL] [Abstract][Full Text] [Related]
20. Repeated administration of growth hormone-releasing hormone with or without previous administration of pyridostigmine in insulin-dependent diabetes mellitus.
Martina V; Bruno G; Tagliabue M; Maccario M; Bertaina S; Zumpano E; Arvat E; Ghigo E; Camanni F
Horm Metab Res; 1997 Apr; 29(4):180-3. PubMed ID: 9178028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
